On March 9, 2022 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, and Stimunity, an early-stage biotech company focused on the development of a unique STING agonist based on virus-like particles, reported data from a collaboration on a STINGactivating therapy, PORT-5 (STI-001) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, Portage Biotech, MAR 9, 2022, View Source [SID1234609762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The stimulator of interferon genes (STING) pathway is a well-recognized immune-boosting pathway and has long been an area of interest in cancer treatment, but STING-activating therapies have historically been limited in clinical trials due to delivery challenges," said Dr. Ian Walters, chief executive officer of Portage. "We are grateful that the scientific committee found the research on our systemically delivered STING-based therapy, PORT-5, to be highly significant and timely to be included in the late-breaking session for AACR (Free AACR Whitepaper) and look forward to sharing further updates in the coming months."

Presentation Details
Abstract Title: Cellular selectivity of STING stimulation determines priming of anti-tumor T cell responses
Abstract Number: 7829
Presenter: Bakhos Jneid, Institut Curie
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date/Time: April 13, 2022, 9:00am – 12:30pm CT
Location: Poster Section 16

On March 9, 2022 Bristol Myers Squibb (NYSE: BMY) reported its participation in the following investor conferences on Wednesday, March 16, 2022 (Press release, Bristol-Myers Squibb, MAR 9, 2022, View Source [SID1234609781]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rupert Vessey, MA, BM, BCh, FRCP, DPhil, Executive Vice President and President, Research and Early Development, will take part in a fireside chat at Guggenheim Healthcare Talks, Targeted Protein Degradation Day. He will answer questions about the company at 10:15 a.m. ET.

Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will take part in a fireside chat at the Barclays’ 2022 Global Healthcare Conference in Miami, Florida. He will answer questions about the company at 1:35 p.m. ET.

Investors and the general public are invited to listen to a live webcast of both sessions during their respective times at View Source Material related to the company’s presentations will be available at the same website at the start of each live webcast. An archived edition of the sessions will be available later that day.

On March 9, 2022 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m. ET (Press release, Wugen, MAR 9, 2022, View Source [SID1234609813]). The presentation will be available to registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 9, 2022 Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, reported that a poster featuring preclinical candidate BBT-207 will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 annual meeting taking place on April 8-13 in New Orleans, Louisiana (Press release, Bridge Biotherapeutics, MAR 9, 2022, View Source [SID1234609828]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following abstract is now available on AACR (Free AACR Whitepaper)’s website.

Presentation Title: BBT-207, a Novel, 4th Generation, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) With Broad-Spectrum Activity to Both Treatment-Emergent and Drug-Naive Mutants for the Treatment of NSCLC

Session Category: Experimental and Molecular Therapeutics

Session Title: Tyrosine Kinase and Phosphatase Inhibitors (PO.ET06.01)

Session Date & Time: Tuesday, April 12, 2022, 1:30 pm — 5:00 pm

Abstract Number: 3346

BBT-207, which is currently under IND-enabling preclinical development, is an internally discovered fourth generation EGFR TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) with potent preclinical activity against a broad range of EGFR mutations in non-small cell lung cancer (NSCLC). Preclinical activity profile of BBT-207 allows it to be positioned in earlier line settings for the first, second and third generation EGFR TKI resistant patients.

BBT-207 was developed with the goal of providing treatment options in earlier line settings such as for patients who harbor C797S double mutations that arise from the progression on the third generation EGFR TKIs in NSCLC.

"We are excited to showcase the preclinical data which suggests that BBT-207 may have the potential to be positioned as a frontline treatment as targeting C797S mutations in NSCLC, especially C797S double mutations," and "we will continue to make advancements of BBT-207 and anticipate submitting the US IND by the end of this year," said Jimmy Jin M.D., Ph.D., the Head of Discovery Biology of Bridge Biotherapeutics.

BBT-207 is planned to enter a Phase I study in metastatic NSCLC in 1H 2023.

On March 9, 2022 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, reported that the Company will showcase its DPX delivery technology in two presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, IMV, MAR 9, 2022, View Source [SID1234609763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Data to be presented suggest that our DPX delivery platform instructs an innate immune response involving NK cells in addition to the previously recognized role for T and B cells," said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc. "This finding supports our clinical strategy to combine our lead compound with other therapies that have a complementary mechanism of action to increase tumor destruction while preserving a favorable safety profile." Translational research using both clinical samples from the DeCidE ovarian cancer trial and tissues from pre-clinical models will be presented showing for the first time that natural killer (NK) cells play a distinct role in promoting anti-tumor responses to the company’s lead DPX-peptide immunotherapeutic, Maveropepimut-S.

In an oral presentation in a late-breaking session about immunotherapeutic combinations, Dr. Olivier Rixe will present safety and efficacy data from the IMV Phase 2 basket study evaluating MVP-S in combination with pembrolizumab and cyclophosphamide in patients with advanced, metastatic bladder cancer. Presentations Details Dr. Rixe and members from the IMV team will attend the conference and both presentations will be available on the conference platform and on the IMV website under the Scientific Publications & Posters section.

NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy

Presenter: Moamen Bydoun, Ph.D., Senior Research Scientist at IMV
Poster Number: 623
Date/Time: Sunday Apr. 10, 2022, 1:30 p.m. – 5:00 p.m. CST

Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer

Presenter: Olivier Rixe, M.D., Ph.D., Quantum Santa Fe, New Mexico
Session Title: Immunotherapy Combination Strategies in Clinical Trials
Presentation Number: CT035
Session Date and Time: Tuesday Apr. 12, 2022, 2:30 p.m. – 4:30 p.m. CST